ASLN ASLAN Pharmaceuticals Limited

1.91
-0.04  -2%
Previous Close 1.95
Open 1.92
Price To Book 3.35
Market Cap 61,215,095
Shares 32,049,788
Volume 2,597
Short Ratio
Av. Daily Volume 22,931

NewsSee all news

  1. ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO

    - Biliary tract cancer (BTC) patients treated with varlitinib plus capecitabine in second line achieved a response rate of 11% including two complete responses, median PFS of 2.7 months and OS of 5.8 months - Patients

  2. Abstract on ASLAN Pharmaceuticals' Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019

    SINGAPORE, Sept. 10, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497)), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on its lead candidate,

  3. New Data From Aslan's Study of Varlitinib in China Accepted as Late-Breaking Oral Presentation at 2019 CSCO Annual Meeting

    SINGAPORE, Aug. 27, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497)), a clinical-stage oncology and immunology focused biopharma company, today announced that a late-breaking abstract detailing

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 4Q 2019.
Varlitinib - TREETOPP
Biliary tract cancer
Phase 2 trial did not meet primary endpoint - January 13, 2019.
Varlitinib
Gastric cancer
Evaluating next steps - noted August 2019.
ASLAN003
Acute Myeloid Leukemia (AML)
Phase 1/2 new data presented at at ASCO Gastrointestinal Cancers Symposium January 2019.
Varlitinib + gemcitabine and cisplatin
Biliary tract cancer
MAD trial to be initiated 2H 2019.
ASLAN004
Atopic dermatitis
Phase 1 presentation due at ESMO September 28, 2019.
Varlitinib + mFOLFIRI
Solid tumors

Latest News

  1. ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO

    - Biliary tract cancer (BTC) patients treated with varlitinib plus capecitabine in second line achieved a response rate of 11% including two complete responses, median PFS of 2.7 months and OS of 5.8 months - Patients

  2. Abstract on ASLAN Pharmaceuticals' Varlitinib Accepted for Poster Presentation at ESMO Asia Congress 2019

    SINGAPORE, Sept. 10, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497)), a clinical-stage oncology and immunology focused biopharma company, today announced that an abstract on its lead candidate,

  3. New Data From Aslan's Study of Varlitinib in China Accepted as Late-Breaking Oral Presentation at 2019 CSCO Annual Meeting

    SINGAPORE, Aug. 27, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497)), a clinical-stage oncology and immunology focused biopharma company, today announced that a late-breaking abstract detailing